Kestra Medical Technologies (NASDAQ:KMTS) Insider Timothy Moran Sells 8,759 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Timothy Moran sold 8,759 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $22.61, for a total transaction of $198,040.99. Following the completion of the transaction, the insider owned 68,725 shares of the company’s stock, valued at approximately $1,553,872.25. This trade represents a 11.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

NASDAQ:KMTS opened at $23.99 on Tuesday. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a 52 week low of $14.10 and a 52 week high of $30.00. The stock’s 50-day moving average price is $22.62 and its 200-day moving average price is $22.48. The stock has a market capitalization of $1.41 billion, a PE ratio of -9.91 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The business had revenue of $28.64 million during the quarter. As a group, equities analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Kestra Medical Technologies

Institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its holdings in Kestra Medical Technologies by 137.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after acquiring an additional 2,529,851 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Kestra Medical Technologies by 180.8% during the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after purchasing an additional 612,343 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Kestra Medical Technologies in the first quarter valued at approximately $11,036,000. Brown Advisory Inc. grew its position in shares of Kestra Medical Technologies by 34.1% in the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after purchasing an additional 428,996 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC acquired a new stake in shares of Kestra Medical Technologies in the fourth quarter valued at approximately $9,282,000.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. BTIG Research increased their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. The Goldman Sachs Group dropped their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Finally, Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Kestra Medical Technologies has a consensus rating of “Hold” and a consensus price target of $27.83.

Key Headlines Impacting Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
• Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.